Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7876188 | 0.81 | POLB (0.58) | MAPTRXFP1MAPK1KMT2AMEN1 | |
| SCHEMBL7876133 | 0.81 | NPSR1 (0.71) | MAPTRXFP1MAPK1KMT2AMEN1 | |
| SCHEMBL7876448 | 0.71 | POLB (0.58) | MAPTKMT2AMEN1 | |
| SCHEMBL27553133 | 0.70 | MEN1 (0.66) | MAPTMAPK1KMT2AMEN1 | |
| SCHEMBL7867465 | 0.70 | NPSR1 (0.57) | MAPTRXFP1KMT2AMEN1 | |
| SCHEMBL7872611 | 0.70 | NPSR1 (0.73) | MAPTRXFP1KMT2AMEN1 | |
| SCHEMBL22995641 | 0.70 | MEN1 (0.61) | MAPTMAPK1KMT2AMEN1 | |
| SCHEMBL4659439 | 0.70 | KDM4E (0.67) | MAPK1KMT2AMEN1 | |
| SCHEMBL4660820 | 0.70 | KDM4E (0.67) | MAPK1KMT2AMEN1 | |
| SCHEMBL5642916 | 0.70 | KDM4E (0.67) | MAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0800505-B1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORP (US) | 2001-09-26 | — | — | EP | claimed |
| US-5801195-A | TUMOR NECROSIS AGENT INHIBITORS FOR COMBATING CACHEXIA, ENDOTOXIC SHOCK AND RETROVIRUS REPLICATION | CELGENE CORPORATION (US) | 1998-09-01 | — | — | US | claimed |
| US-5736570-A | ADMINISTERING TO REDUCE TUMOR NECROSIS FACTOR (TNFA) LEVELS IN MAMMAL; RETROVIRAL DISEASE TREATMENT/PROPHYLAXIS | CELGENE CORPORATION (US) | 1998-04-07 | — | — | US | claimed |
| EP-0800505-B1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORP (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6046221-A | USEFUL FOR REDUCING LEVELS OF TUMOR NECROSIS FACTOR-ALPHA IN A MAMMAL | CELGENE CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
| US-5801195-A | TUMOR NECROSIS AGENT INHIBITORS FOR COMBATING CACHEXIA, ENDOTOXIC SHOCK AND RETROVIRUS REPLICATION | CELGENE CORPORATION (US) | 1998-09-01 | — | — | US | disclosed |
| US-5736570-A | ADMINISTERING TO REDUCE TUMOR NECROSIS FACTOR (TNFA) LEVELS IN MAMMAL; RETROVIRAL DISEASE TREATMENT/PROPHYLAXIS | CELGENE CORPORATION (US) | 1998-04-07 | — | — | US | disclosed |